3SBio (OTCMKTS:TRSBF – Get Free Report) is expected to be posting its results after the market closes on Thursday, August 20th. Analysts expect 3SBio to post earnings of $0.0942 per share and revenue of $689.3230 million for the quarter.
3SBio Stock Performance
3SBio stock opened at $2.12 on Tuesday. The firm’s 50 day moving average price is $2.15 and its two-hundred day moving average price is $2.53. 3SBio has a twelve month low of $2.00 and a twelve month high of $4.74.
About 3SBio
3SBio Inc (OTCMKTS: TRSBF) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of protein-based therapeutics and chemical drugs. Established in 1999 and headquartered in Shenyang, Liaoning Province, the company has built an integrated platform that encompasses in-house R&D capabilities, clinical development, commercial production and a nationwide sales network.
The company’s product portfolio features a range of hematopoietic growth factors such as recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human erythropoietin (rhEPO), insulin and insulin analogs, hemostasis agents and monoclonal antibodies.
See Also
- Five stocks we like better than 3SBio
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for 3SBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 3SBio and related companies with MarketBeat.com's FREE daily email newsletter.
